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Abstract 
Lipid-based formulations encompass a diverse group of formulations with very 
different physical appearance, ranging from simple triglyceride vehicles to more 
sophisticated formulations such as self-emulsifying drug delivery systems 
(SEDDS). Lipid-based drug delivery systems may contain a broad range of oils, 
surfactants, and co-solvents.  They represent one of the most popular 
approaches to overcome the absorption barriers and to improve the 
bioavailability of poorly water-soluble drugs.  Diversity and versatility of 
pharmaceutical grade lipid excipients and drug formulations as well as their 
compatibility with liquid, semi-solid and solid dosage forms make lipid systems 
most complex. Digestion of triglyceride lipids, physicochemical characteristics 
and solubilisation of lipid digestion products as well as intestinal permeability 
are some of the variable parameters of such formulations. Furthermore, among 
the factors affecting the bioavailability of the drug from lipid-based formulations 
are the digestion of lipid, the mean emulsion droplet diameter, the lipophilicity of 
the drug and the type of lipids.  The solubility of  the Active Pharmaceutical 
Ingredient in the Lipid System, the desorption /sorption isotherm and the 
digestibility of lipid vehicle are important issues to be considered for 
formulations of isotropic lipid formulations. This review also describes the fate of 
lipid formulations in the gut and the factors influencing the bioavailability from 
lipid-based formulations. Novel formulation systems and currently marketed 
products conclude this review. 
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Introduction 
Oral lipid-based products entered the market in 1981 and currently account for 
approximately 3% of commercially available oral formulations. Lipids are ubiquitously 
distributed compounds that play fundamental roles in the architecture and functionality of 
all living cells and therefore are most commonly studied as components of foodstuff and 
important energy sources in enteral nutrition [1].  The total daily dose of active 
pharmaceutical excipient (API) administered by these formulations ranges from 0.25 µg to 
2000mg. For capsules, the amount of active drug substance per dosage unit ranges from 
0.25 µg to 500 mg, and for oral solutions from 1 µg/ml to 100 mg/ml. The total amount of 
lipid administered in a single capsule ranges from 0.5 to 5 g, but can be 0.1 ml up to 20 ml 
for oral solutions [2]. Lipid-based formulations range in complexity from simple, one-
excipient solutions based on e.g. sesame or corn oil to multi-excipient, self-emulsifying 
drug delivering systems (SEDDS). The excipients in lipid-based formulations include 
water-insoluble triglycerides (e.g., corn oil, olive oil, peanut oil, sesame oil, soyabean oil, 
rapeseed oil, hydrogenated vegetable oil, hydrogenated soybean oil and medium chain 
triglycerides of coconut oil and palm seed oil), organic liquids/semisolids (e.g., beeswax, 
DL-α-tocopherol, oleic acid, medium chain mono and diglycerides, propylene glycol ester 
of fatty acids), nonionic surfactants (e.g., cremophor EL, cremophor RH 40, cremophor RH 
60, d-α-tocopherol propylene glycol 1000 succinate, glyceryl monooleate, polysorbate 20, 
polysorbate 80, Sorbitan monolaurate, Labrafil M-1944CS, Labrafil
®  M-2125CS, and 
Labrasol
®), a phospholipid (phosphatidylcholine), and water-miscible organic solvents 
(polyethylene glycol 400, ethanol, propylene glycol, glycerin).  
There is increasing demand to develop suitable drug carrier systems in order to control, 
localize and improve drug delivery. At that, many natural and synthetic lipids are aimed to 
improve oral bioavailability of poorly water-soluble drugs. When administered in hydrophilic 
form of solid formulations, these compounds exhibit low bioavailability as their absorption 
can be dissolution- and capacity-limited due to poor solubility. 
Lipid formulations can reduce the inherent limitation of slow and incomplete dissolution of 
poorly water-soluble drugs and facilitate formation of solubilised phases from which 
absorption may occur [3]. The solubilised phases most likely arise from intralaminal 
processing after lipid absorption. The co-administration of lipids with drugs can also impact 
their absorption pathway [4]. Although most orally administered compounds gain access to 
the systemic circulation via the portal vein, some highly lipophilic drugs are transported 
directly to the systemic circulation via intestinal lymphatics, which improves oral 
bioavailability of API. 
Lipids open a wide array of different formulations for oral administration because they can 
be  manufactured as solutions, suspensions, emulsions, self-emulsifying systems and 
micro-emulsions [4]. Lipids offer the potential for enhancing drug absorption and oral 
bioavailability. This review is aimed to provide an overview, how lipid-based formulations 
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Impact of the GI-tract on Lipids and Lipid-Based Formulations 
The GI-tract  basically influences the performance of lipid-based formulations as 
triglycerides and their derivatives are quantitatively hydrolyzed prior to absorption. After a 
meal, the presence of lipid digestion products induces secretion of pancreatic and biliary 
fluids which alter the luminal environment of the small intestine [5]. The lipid digestion 
products, being better water-soluble than the parent triglyceride, are solubilized within bile 
salt mixed micelles and for their subsequently delivered to absorptive cells of the GI-tract. 
The chemistry and nature of the interaction of lipid digestion products with the aqueous 
contents of the GI-tract change as a function of digestion and solubilization. 
Digestion of triglycerides 
Intestinal absorption of the products of lipid digestion is the result of three sequential 
processes, which involve (i) dispersion of fat globules (ingested lipids) to yield a coarse 
emulsion of high surface area, (ii) enzymatic hydrolysis of the fatty acid glyceryl esters 
(primarily triglyceride lipids) at the oil/water interface and (iii) dispersion of the lipid 
digestion products into an absorbable form [6]. Salivary glands secrete lingual lipase and 
gastric mucosa secretes gastric lipase, which initiate triglyceride (TG) hydrolysis to the 
corresponding diglyceride (DG) and fatty acid (FA) within the stomach. The pH-optimum 
ranges for lingual and gastric lipase from 3 to 6, and medium chain triglycerides are 
hydrolyzed at a faster rate than long chain triglycerides [7].  
TG are preferably hydrolysed by pancreatic lipase, an interfacial enzyme, which 
preferentially acts at the surface of emulsified TG droplets to quantitatively convert TG into 
the corresponding 2-monoglyceride (MG) and two fatty acids (FA).  Optimum activity is 
observed when oleate is the fatty acid, and it decreases towards shorter chain 
triacylglycerols and soluble carboxyl esters substrates. Bile salts at concentrations usually 
present in the duodenum inhibit binding of pancreatic lipase at the oil-water interface. 
Further classes of biliary-derived lipids are the phospholipids (e.g., phosphatidylcholine, 
PC) playing an important role as solubilisers for lipid digestion products. Prior to 
absorption, PC is hydrolyzed by phospholipase A2  to  lysophophatidylcholine (lyso-PC), 
with the majority of PC present in the intestine secreted in bile (10–20 g/day) with only 
modest dietary influence. Model for the sequential steps involved in lipid digestion is given 
in Fig. 1.  
Physical chemistry, absorption and solubilisation of lipid digestion products 
Bile plays a key role in solubilisation of lipid digestion products and poorly water-soluble 
drugs [4]. The presence of lipid digestion products as well as cholecystokinin-mediated 
contraction of the gall bladder and relaxation of the sphincter of Oddi leads to expulsion of 
bile, with peak flow occurring approximately 30 min after ingestion of a meal. 
Typical concentrations of bile salts in the fasted intestine are 4–6 mM compared with post-
prandial concentrations of 10–20 mM [8]. The inclusion of the lipidic components 
decreases the critical micelle concentration (CMC) and an increase the size and 
solubilisation capacity of the micelles, e.g., the inclusion of lecithin and MG decreases the 
CMC of mixed micellar systems to values less than 1 mM. Therefore, it is likely that the 
CMC of mixed bile salt systems present in the intestine is surpassed even in the fasted 708  B. K. Nanjwade et al.:   
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state. Although the specific mechanisms of absorption of the lipid digestion products have 
not  been elucidated yet, the common role of the intestinal mixed micellar phase to 
solubilise these poorly water-soluble compounds and to provide a concentration gradient 
for absorption of lipids and presumably of drugs solubilised in this phase is generally 
accepted. Micelles are not absorbed intact, and lipids are suggested to be absorbed from 
a monomolecular intermicellar phase [9–11]. The dissociation of monomolecular lipids 
from the mixed micellar phase prior to absorption may be stimulated by a microclimate of 
lower pH at the intestinal absorptive site [12, 13]. 
Lipids and GI-transit profiles 
The products of lipid digestion delay gastric emptying, and much pharmaceutical interest 
has focused on the relationship between gastric emptying, food ingestion, and the transit 
behavior of non-disintegrating controlled release dosage forms. Although there is little 
information as to how small pharmaceutically relevant volumes of lipid impact on transit 
profiles, it is likely that any effect would not significantly impact the bioavailability of the co-
administered drug [4]. 
Lipids and intestinal permeability 
Constituents of the mixed micellar phase can modify the intestinal permeability of poorly 
water-soluble compounds via three mechanisms. Firstly, the presence of lipid digestion 
products and bile salts may alter the intrinsic permeability of the intestinal membrane, 
leading to increased absorption via paracellular or transcellular routes. Secondly, 
solubilisation of lipophilic drugs within bile salt mixed micelles may facilitate diffusion 
through the aqueous diffusion layer, improving absorption. Thirdly, and conversely, drug 
solubilisation may decrease the intermicellar ‘free’ fraction of drug, which could potentially 
lead to a decrease in absorption. These divergent effects are likely to provoke sometimes 
contradictory reports about drug absorption after administration as solubilised surfactant-
based systems [8]. 
Factors Affecting Bioavailability of Lipid-Based Formulations 
Lipid Digestion 
If the drug possesses high affinity to the lipid vehicle, it can be assumed that the API 
moves apparently together with vehicle in the GI-tract, revealing that digestibility of lipid 
would be as important as gastric emptying rate of the same. Thus, careful selection of the 
lipid vehicle can control the absorption rate of drug. GI lipid digestion consists of three 
sequential steps: (i) the dispersion of fat globules to yield a fine emulsion, (ii) the 
enzymatic hydrolysis of fatty acid esters at the emulsion-water interface, and (iii) the 
desorption and dispersion of insoluble lipid products for subsequent absorption [14, see 
Fig. 2].    Functions of Lipids for Enhancement of Oral Bioavailability of Poorly Water-Soluble Drugs  709 
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Fig. 1.   Model for sequential steps involved in lipid digestion  
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Fig. 2.   Schematic diagram of the fate of lipids in the gut. 
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The API accumulated at the surface of the absorptive epithelium is taken up by 
enterocytes. Certain drugs and surfactants reduce the activity of efflux transporters in the 
GI-wall and, hence, increase the fraction of drug absorbed. Because of the interplay 
between P-gp and CYP3A4 activity, this mechanism may reduce intracellular metabolism 
as well. Non-digestible lipids, including mineral oils, sucrose polyesters and others, are not 
absorbed from the gut lumen. They remain in the gastrointestinal lumen, tend to retain the 
lipophilic drug within the oil, and thus, may limit the absorption of the drug. Consequently, 
lipids that are not affected by negative effects of surfactant such as medium chain 
monoglycerides, fatty acids, and monoesters of fatty acids are preferred as vehicles for 
lipid delivery systems. 
Mean emulsion droplet diameter: 
The mean emulsion droplet diameter is a parameter indicating the quality of self-
emulsifying formulations. The droplet size of SEDDS upon dilution with aqueous media is 
primarily influenced by the type and concentration of emulsifier: The higher the 
concentration of emulsifier, the smaller the emulsion droplet and the faster the drug 
release. Two techniques are commonly used to determine the mean emulsion droplet 
diameter: low angle laser light diffraction is applied for emulsions with droplet sizes > 1µ 
and quasi-elastic light scattering for investigations of submicron dispersions. [15–17]. 
In addition, the mean emulsion droplet diameter seems to be a very critical factor for 
prediction of the in-vivo performance of undigested lipid-based formulations, such as long 
chain triglycerides in case of Cyclosporine (Neoral
®  versus Sandimmune
®) [18]. 
Nevertheless, in case of predigested lipids such as medium chain monoglycerides or 
propylene glycol monoester of C8-C10 fatty acids, the mean emulsion droplet diameter 
may not be crucial in-vivo. 
Lipophilicity of the API 
Highly hydrophobic drugs (log P > 6) can be taken up into the lymphatic system by 
partitioning into chylomicrons in the mesentery vein [19] which has been demonstrated to 
be crucial for the absorption of the anti-malaria compound halofantrine [20, 21]. 
Furthermore, highly lipophilic retinoids are known to be transported in the intestinal lymph 
after oral administration.  
Type of lipids 
The nature or type of lipids is important because digestible lipids may influence absorption 
in a manner differing from that of non-digestible lipids. Commonly used digestible lipid 
vehicles are listed in table 1. The lower the melting point of the fatty acid, the higher is the 
amount of drug absorbed.  
Drug release 
Primarily, the characteristics of drug and lipid as well as their aqueous solubility are key 
factors that control drug release and absorption from lipid-based formulations [22]. Other 
issues to be considered are whether the drug is formulated in oil, SEDDS or emulsified 
form, the absorption pathway of the drug, the droplet size of the emulsion present in the 
intestine, the type of surfactants, the metabolic pathway of the lipids and the changes in 
gastric motility due to presence of lipids. 712  B. K. Nanjwade et al.:   
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Tab. 1.   Commonly used lipid vehicles for lipid-based formulations. 
Classification  Lipophilic vehicles 
Fatty acids  Oleic acid, Myristic acid, Caprylic acid, 
Capric acid 
Ethyl esters   Ethyl Oleate 
Triglycerides of long-chain fatty acids  Soybean Oil, Peanut Oil, Corn Oil 
Triglycerides of medium-chain fatty acids  Miglyol
® 812, Captex
® 355, Labrafac
® 
 
Crucial Issues during Development of Isotropic Lipid Solutions 
The physico-chemical properties of the API as well as the choice of lipids play a major role 
in designing isotropic solutions and will decide whether it will be a simple lipid solution, a 
SEDDS or a SMEDDS. Some of the physico-chemical parameters, which influence the 
design of isotropic solution, include: 
Solubility of API in the Lipid System 
Solubility is one of the major factors that limit the use of lipid-based delivery systems. The 
amount and the solubility of the drug in the lipid vehicle are decisive whether an isotropic 
lipid formulation is formed or not. Factors that can impact solubility include: 
Solubility Parameters 
The solubility characteristics are useful as a predictive tool for the selection of a solvent or 
solvents for a particular application. Solubility parameters give a systematic estimate for 
the compatibility between two components. As a  rule of thumb two substances are 
miscible when their Hildebrand solubility parameters are close to each other or when the 
difference in their solubility parameters is less than 2 MPa
1/2. Checking the Hildebrand 
solubility parameters is an effective way to predict the formulation characteristics of a 
particular compound. 
Hydrophilic-Lipophilic Balance (HLB) 
The HLB is an empirical formula that is used to characterize surfactants and to select 
those appropriate for preparation of microemulsions [23, 24]. Non-ionic and ionic 
surfactants are often considered for pharmaceutical applications because they are less 
toxic [26] and less affected by pH and ionic strength changes. The HLB value of each lipid 
vehicle is calculated according to: 
HLB = 20
1 – S
A
 
where S is the saponification number of the ester and A is the acid number of the fatty acid 
[27]. The higher the HLB value of the surfactant, the broader is the range to obtain micro-
emulsions. Emulsifiers with HLB > 10, which are commonly used in isotropic lipid-based 
solutions, are summarized in table 2. Co-emulsifiers with HLB values ranging from 4 to 6, 
which are commonly used in isotropic lipid-based solutions, are given in table 3.   Functions of Lipids for Enhancement of Oral Bioavailability of Poorly Water-Soluble Drugs  713 
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Tab. 2.   Commonly used emulsifiers in isotropic lipid based formulations. 
Classification  Emulsifiers 
PEGylated glycerides 
PEG-8 glyceryl caprylate/caprate (Labrasol
®) 
PEG-32 glyceryl laurate (Gelucire
® 44/14) 
PEG-32 glyceryl palmito stearate (Gelucire
® 50/13) 
Polyoxyethylene sorbitan fatty 
acid esters  
Polyoxyethylene 20 sorbitan monolaurate (Tween
® 20) 
Polyoxyethylene 20 sorbitan monostearate (Tween
® 60) 
Polyoxyethylene 20 sorbitan monooleate (Tween
® 80) 
Sorbitan fatty acid esters  
Sorbitan monolaurate (Span
® 20) 
Sorbitan monostearate (Span
® 60) 
Sorbitan monooleate (Span
® 80) 
Polyoxyethylene castor oil 
derivatives   Polyoxyl 35 castor oil (Cremophor
® EL) 
Polyethylene glycol based 
derivatives of Vitamin E 
d-Alpha-Tocopheryl Polyethylene Glycol-1000 Succinate 
(TPGS) 
Phospholipids, PEG based 
Phospholipids   Lecithin, Modified Lecithin 
 
Tab. 3.   Commonly used co-emulsifiers in Isotropic lipid-based formulations. 
Classifications  Co-emulsifiers 
PEGylated glycerides  PEG-6glyceryl monooleate (Labrafil
® M1944 
CS) 
Monoglycerides of long-chain fatty acids Glycerol monooleate, Glycerol monostearate 
Monoglycerides of medium-chain fatty 
acids  Glyceryl caprylate/caprate (Capmul
® MCM) 
Mono and diglycerides of medium-chain 
fatty acids  Imwitor
® 972, Imwitor
® 988 
Propylene glycol monoester of medium-
chain fatty acids 
Propylene glycol monocaprylate (Capmul
® 
PG-8; Capryol
® 90) 
Propylene glycol diester of medium-
chain fatty acids 
Propylene glycol dicaprylate/dicaprate (Captex
® 
200) 
Poly-glycerol esters  Glyceryl tri-oleate, decaglycerol mono-oleate 
 
Partition Coefficient 
This factor describes the lipophilicity of a molecule corresponding to the partition 
coefficient of a compound between a lipophilic and a hydrophilic phase, usually 1-octanol 
and water [28]. The partition coefficient is the concentration of the drug in the organic layer 
divided by that in the aqueous one. Finally, log P is defined as the decadic logarithm of P.  
Compounds with log P>4 (i.e., being more lipophilic) are likely to be dissolved in oils. 
Compounds with intermediate log P (log P<4) may require a mixture of hydrophilic 
surfactants (HLB 4-12) or water-soluble co-solvents to form a self-emulsifying system with 
maximum solubility. Interestingly, a compound with high log P cannot necessarily exhibit 714  B. K. Nanjwade et al.:   
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high solubility in oil, whilst another compound may be highly soluble in oil but showing a 
relatively low log P value [29].  
Phase Diagrams of lipid formulations 
A phase diagram of the lipid formulation for a given API should be individually established 
by varying the ratio of drug, oil, and surfactant due to the impact of the physico-chemical 
properties of the drugs such as inherent polarity and surface activity. That way, different 
regions for good, intermediate, and poor self-emulsification are recognized. In addition, 
phase studies are performed by diluting a mixture of oil-surfactant sequentially with 
increasing amounts of water. After equilibrium, the phase type is identified using a crossed 
polarized viewer and an optical microscope (Fig. 3). 
 
 
Fig. 3.   Schematic diagram of an Equilibrium phase for Type II SEDDS system (from 
Dumanli, I., Characterization of gelling phenomenon of a lipid-based 
formulation. Master Thesis, University of Rhode Island, 1998). 
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Drug Loading 
It can affect long-term physical stability of the drug product. As a prerequisite, the 
saturation concentration of the API in the lipid-based formulation should be carefully 
established and drug loading has to be optimized in order to avoid potential gelling or drug 
crystallization under shear stress and/or during storage. Drastic changes in emulsifying 
properties as indicated by an increasing mean emulsion droplet diameter due coalescence 
and/or aggregation indicate product instability. 
Sorption/desorption (hygroscopicity) Isotherm 
Hygroscopicity of the lipid may induce dehydration of the soft gelatin capsule and hard 
gelatin capsule shell, resulting in brittleness. Impact of temperature and moisture on the 
drug solubility characteristics must be investigated. Potential solute migration into the shell 
must be characterized during the formulation development, particularly when such a drug 
has good solubility in glycerin and sorbitol, which are commonly used plasticizers in soft 
gelatin capsules. 
Shear effect 
Prolonged shearing was shown to change the rheological behavior of an amorphous drug 
from Newtonian to pseudoplastic after dissolution in mono- and diglycerides [30]. Changes 
in the viscous modulus determined by oscillatory measurements indicate formation of 
structural elements due to presence of hydrogen bonds between drug and the vehicle. 
These interactions can also be detected by DSC and FT-IR. Moreover, the shear effect 
was shown to depend on drug concentration. Supersaturated drug solutions are more 
likely prone to gelation upon shear stress and/or precipitation upon the storage.  
Lipid Formulations And Oral Bioavailability 
The simplest approach to evaluate absorption of drugs from lipid-based systems is to 
prepare a solution or suspension in lipids and do in-vivo assays (see table 4). 
Tab. 4.   Lipid formulations with improved oral bioavailability of API 
Compound  Study Design  Formulation  Observation and comments 
Phenytoin [31] 
BA study in rats 
after gastric 
administration 
Corn oil 
suspension, corn 
oil emulsion 
BA and Cmax from emulsion> corn 
oil suspension> aqueous 
suspension 
Steroid [32]  Oral BA study in 
rats 
Solution and 
suspension in 
sesame oil 
BA from lipid solution 3-fold> 
aqueous suspension, absorption 
was a function of solubilised drug 
Lipophilic pro-
drugs of 
phenytoin [33] 
BA study in rats 
after gastric 
administration 
Solution in short 
chain fatty acid, TG 
BA 4-fold > solution of phenytoin 
sodium 
Antimalarial 
amine [34] 
Oral BA study in 
beagle dogs  Oleic acid solution  BA from lipid solution 3-fold > 
standard capsule 
Cinnarizine [35]  Oral BA study in 
beagle dogs  Oleic acid solution  BA from lipid solution 4-fold > 
standard tablet 
BA…bioavailability. 716  B. K. Nanjwade et al.:   
Sci Pharm. 2011; 79: 705–727 
An early stimulus for the use of lipid vehicles for drug formulation was the observation of 
improved bioavailability when poorly water-soluble drugs were co-administered with food. 
A well-known example is the suspension of phenytoin in corn oil [31] which considerably 
improved oral bioavailability as compared to the aqueous suspension. 
Abrams et al. studied the oral dose proportionality of a lipophilic steroid derivative, 
(5α,17β)-2-chloro-3-[(4-nitrophenoxy)imino]androstan-17-yl acetate (an  o-aryl oxime of 
2α-chlorodihydrotestosterone; nisterime acetate) when administered to rats as either 
solution in sesame oil or aqueous suspension [32]. The threefold higher bioavailability from 
sesame oil solution was attributed to improved solubilisation and dissolution in oil, which 
represent prerequisites for enhanced absorption. 
Unfortunately, many poorly water-soluble drugs also exhibit limited solubility in 
pharmaceutically relevant lipids. A promising approach to improve lipid solubility of drugs 
with insufficient lipid solubility is the design of low melting, lipophilic prodrugs. For 
example, Yamoka et al. took account for the low equilibrium lipid solubility of phenytoin by 
synthesising a range of low melting prodrugs with enhanced lipid solubility [33].  
The enhancement in oral bioavailability of a hydrophobic amine antimalarial, prepared as 
an oleic acid solution in a soft gelatin capsule, is typical for the situation where formulation 
of a poorly water soluble drug in lipid can provide effective oral delivery [34].  
Oral administration as a solution in oleic acid was also effective in enhancing the 
absorption of cinnarizine. [35]. 
Digestibility of the Lipid Vehicles 
Lipids are typically classified according to their chemical structure, polarity, characteristics, 
and degree of interaction with water. Nevertheless, when assessing lipids as vehicles, 
their digestibility has to be considered. Non-digestible lipids such as mineral oil, e.g. liquid 
paraffin and sucrose polyesters, essentially remain unabsorbed in the intestinal lumen and 
can actually limit or even reduce drug absorption by retaining a considerable amount of co-
administered drug. Digestive lipids comprise dietary lipids such as glycosides, fatty acids, 
phospholipids, cholesterol esters as well as various synthetic derivatives. The rate and 
extent of digestion, the colloidal phases formed and pharmacological effects of the 
digestion products represent potential factors influencing release of the API from the 
vehicle and its absorption. Table 5 lists selected studies where the effects of different lipids 
on drug absorption have been investigated. 
Patton and Gilford demonstrated improved oral bioavailability of triamterene in rats when 
administered in 1ml lipid solution as compared to aqueous suspensions [36]. 
Myers and Stella [37] investigated the effects of non-digestible and digestible lipid vehicles 
on the oral bioavailability of penclomedine, a highly lipophilic, poorly water-soluble 
cytotoxic agent. The absolute bioavailability of penclomedine in the rat after administration 
in various lipids is higher than that of the aqueous suspension. 
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Tab. 5.   Influence of the digestibility of the lipid vehicle on the rate and extent of drug 
absorption. 
Compound  Study 
Design 
Lipids  Observation and 
comments 
Triamterene 
[36] 
Oral BA study 
in rats 
Peanut oil, oleic 
acid, triolein 
BA from OA > PO > TO ≥ 
aqueous suspension. With 
20 μl volumes, PO ≅ 
aqueous suspension 
Penclomedine 
[37] 
BA in rats 
after 
intraduodenal 
administration 
SCT / MCT / LCT, 
mineral oil 
BA from MCT > LCT > 
mineral oil > SCT > aqueous 
suspension; BA a function of 
digestibility of vehicle 
Cyclosporine 
[38] 
Intraduodenal 
administration 
to rats 
Lipid micro 
emulsion 
Absorption decreased in bile 
duct ligated and 
pancreatomised rats 
BA…bioavailability. 
 
The dependency of cyclosporine absorption on bile secretion has also been evaluated 
after administration of a coarse lipid emulsion to liver transplant patients with a T-tube 
inserted in their common bile duct [38]. The absorption of cyclosporine was assessed 
before and after clamping the T-tube (i.e. with or without bile diversion) and the relative 
bioavailability of cyclosporine was 3–4 fold higher in the patients without bile diversion. 
Novel Lipid Formulations 
The carrier systems that have been most extensively studied to control the release of the 
incorporated substances are: 
•  Liposomes 
•  Polymeric nano- and microparticles 
•  Solid lipid nanoparticles (SLNs) 
•  Self-emulsifying drug delivery systems (SEDDS) 
Liposomes are spherical particles composed of one or more concentric phospholipid 
bilayers. This kind of structure makes it possible to incorporate lipophilic drugs into lipid 
bilayers as well as hydrophilic drugs into the aqueous compartment. Drug release from 
liposomes, stability, and pharmacokinetic profiles depend on composition, size, surface 
charge, and drug solubility. Liposome formulations of many different drugs show a 
significant increase in therapeutic activity compared with non-liposomal formulations. 
Liposomes are mostly biocompatible and biodegradable, but also face some 
disadvantages including low stability, low encapsulation efficiency, and difficult scale-up 
[38–42].  
Polymeric nano-  and microparticles are general terms that include spheres as well as 
capsules. Hydrophilic and lipophilic drugs can be incorporated or entrapped into these 
polymeric carriers, but reaching therapeutic levels is one the most crucial issues. These 718  B. K. Nanjwade et al.:   
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kinds of drug carrier systems have proved to be more stable than liposomes both in-vivo 
and during storage. Their main disadvantages are that preparation methods sometimes 
require organic solvents and that large-scale production is rather difficult. Moreover, it is 
sometimes crucial to find appropriate polymers that are confirmed to be nontoxic, 
biodegradable and nonimmunogenic [39–45]. Some synthetic polymer matrices have also 
been suspected to exert detrimental influence on peptides and proteins incorporated 
during the manufacturing process [45]. 
SLNs were developed in the early 1990s and represent promising drug carrier systems, 
especially in terms of mediating a sustained-release profile of the incorporated API. SLNs 
are in the submicron size range (50–1000 nm) and built from a lipidic matrix being solid at 
room temperature. They seem to represent an alternative drug carrier system to liposomes 
and polymeric nanoparticles. SLNs indeed combine several of their advantages while 
avoiding some of their disadvantages [46, 47]: (i)  the lipids used are similar to 
physiological lipids so that toxicity is reduced. (ii) SLNs are physicochemically stable and 
can be produced easily on a large industrial scale. In addition, (iii) raw materials and 
production costs are relatively low. Their  most important limitation is that the drugs 
incorporated into SLNs have to be sufficiently lipophilic to guarantee high entrapment 
efficiency. So far, SLNs have been studied for parenteral, oral, and topical administration 
[48–50].  
Whereas the composition of solid lipid microspheres is equivalent to SLNs, their size is in 
the micrometre range. Given similar composition, these lipophilic particles may also be 
considered as physiologically compatible, physicochemically stable, and appropriate for 
up-scaled  production. Only the difference in size between SLNs and solid lipid 
microparticles will decide on their application fields and administration.  
The utility of solubilizing lipid based formulations to improve the gastro intestinal 
absorption of poorly water-soluble, hydrophobic drugs is well documented [1, 4]. It is 
suggested that improved absorption is predominantly due to the higher solubilisation rate 
representing a prerequisite for absorption  in the GI-tract. Other mechanisms proposed 
include protection of the API inside the lipophilic vehicle from chemical and enzymatic 
degradation, which is localized in the aqueous environment, and promotion of lymphatic 
drug transport, which escapes hepatic first pass metabolism [19].   
Use of lipid-based, self-emulsifying drug delivery systems (SEDDS) and self-micro-
emulsifying drug delivery systems (SMEEDS) represent alternative formulations for 
improving oral absorption of poorly water-soluble drugs. 
SEDDS and SMEDDS are easily manufactured and physically stable isotropic mixtures of 
oil, surfactants, co-surfactants and solubilised drug substance that are administered orally 
in soft or hard gelatin capsules. SMEDDS readily disperse in the GI-tract, where the 
motility in the stomach and intestine allow for emulsification [15]. Self-emulsifying 
properties are conferred by a proper selection of the lipid/surfactant pair as well as the 
optimum ratio of lipid and surfactant [15, 16]. In order to reach the optimum HLB value 
required for the emulsification, mixtures of different surfactants are in use [51].  
The lipid droplets formed in self-emulsifying formulations may facilitate drug absorption 
directly, independent from the bile salt mediated mixed micelle transport system. The   Functions of Lipids for Enhancement of Oral Bioavailability of Poorly Water-Soluble Drugs  719 
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improved drug absorption provided by self-emulsifying formulations, however, depends on 
the maintenance of the drug in the solubilised state before it can be absorbed from the 
GI-tract. 
Marketed Lipid-Based Dosage Forms 
Lipids are versatile tools for drug administration because they cover a wide array  of 
different types of formulations, such as solutions, suspensions, emulsions, self-emulsifying 
systems, lipid particles, and microemulsions. The commercially available oral lipid-dosage 
forms are either filled in capsules or represent bulk oral solutions. Both soft and hard 
gelatine capsules are used for lipid-based formulations. Usually, liquid formulations are 
manufactured either as soft or hard gelatine capsules, whereas semisolid or solid 
formulations are filled into hard gelatine capsules. Parenteral  formulations include 
emulsions, microemulsions, liposomes, lipid complexes, suspensions, and colloidal 
dispersions. 
The different kinds of formulations are generally divided into following categories: 
•  One-lipid excipient formulations 
•  Two-lipid excipients formulations 
•  Three-lipid excipients formulations 
•  Four-lipid excipients formulations 
•  Extended release formulations 
•  Microemulsions  
•  Oral suspensions s 
•  Oral solutions  
One-lipid excipients formulations 
The simplest lipid-based formulations contain only one excipient such as oleic acid, α-
tocopherol, corn oil, peanut oil, sesame oil, medium chain triglycerides, or medium chain 
mono- and diglycerides. All such oral formulations are marketed in soft gelatin capsules. 
Many of the over-the-counter sold products contain polyethylene glycol or medium chain 
triglycerides as the solubilizing excipients (see Table 6). 
Tab. 6.   Marketed one-lipid excipient formulations 
Marketed 
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Heminevrin
®  Clomethiazole  Capsule (soft gelatin)  AstraZeneka  UK 
Marinol
®  Dronabinol  Capsule (soft gelatin)  Solvay 
Pharmaceuticals  USA 
Epadel
®  Ethyl  
icosapentate  Capsule (soft gelatin)  Mochida 
Pharmaceuticals  Japan 
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Two-excipients formulations  
The next level of complexity in lipid-based formulations is reached by those that contain 
two  excipients.  Some  typical  combinations  are  sesame  oil  with  α-tocopherol, medium 
chain triglycerides with ethanol, and propylene glycol esters of fatty acids with glyceryl 
mono-oleate (see Table 7). 
Tab. 7.   Marketed two-lipid excipient formulations 
Marketed 
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Alfarol
®  Alfacalcidol  Capsule (soft gelatin), 
solution and powder 
Chugai 
Pharmaceuticas  Japan, Taiwan 
Hectorol
®  Doxercalciferol  Capsules (soft gelatin)  Draxis Pharma  USA 
Glakay
®  Menatetrenone  Capsules (soft gelatin)  Eisai Co., Ltd.  Japan 
 
 
Three-excipients formulations 
Ascending the scale in complexity, lipid-based formulations containing mixtures of three 
excipients have to be mentioned. Typical examples of such combinations include: (i) 
TPGS, polyethylene glycol (PEG) 400, and PG; (ii) oleic acid, cremophor EL, and ethanol 
or PG; iii) polysorbate 20, PEG 400, and povidone; (iv) medium chain mono-  and 
diglycerides, α-tocopherol, and povidone; and (v) medium chain triglycerides, glycol esters 
of fatty acids, and aspartic acids (see Table 8).  
Tab. 8.   Marketed three-lipid excipient formulations 
Marketed  
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Agenarase
®  Amprenavir  Capsule (soft gelatin)  GlaxoSmithKline  USA 
Targretin
®  Bexarotene  Capsule (soft gelatin) 
Ligand 
Pharmaceuticals 
Incorporated 
USA 
Norvir
®  Ritonavir  Capsule (soft gelatin)  Abbott Laboratories  USA 
 
 
Four-excipients formulations 
The most complex lipid-based formulations currently marketed contain mixtures of four 
excipients such as (i) ethanol, cremophor EL, propylene glycol and mono/diglycerides of 
caprylic/capric acid; (ii) rapeseed oil, beeswax, hydrogenated soyabean, and partially 
hydrogenated plant oils. All the formulations are marketed in soft gelatin capsules (see 
Table 9). 
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Tab. 9.   Marketed four-lipid excipient formulations 
Marketed  
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Aptivus
®  Tipranavir  Capsule (soft gelatin) 
Boehringer 
Ingelheim 
Pharmaceuticals 
USA 
Lamprene
®  Clofazimine  Capsule (soft gelatin)  Novartis  Switzerland 
Infree
®  Indomethacin farnesil  Capsule (soft gelatin)  Eisai Co., Ltd  Japan 
 
 
Extended release formulations 
There are at least three commercially available extended release formulations that contain 
lipid excipients that are filled into hard gelatin capsules (see Table 10). 
Tab. 10.   Marketed lipid-based, extended release formulations. 
Marketed  
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Ketas
®  Ibudilast  Capsule (hard gelatin)  Kyorin Pharmaceutical 
Co., Ltd.  Japan 
Detrol
® LA  Tolterodine 
Tartarate  Capsule (hard gelatin)  International Processing 
Corporation  USA 
MXL
®  Morphine 
Sulphate  Capsule (hard gelatin)  Napp Pharmaceuticals 
Limited  UK 
 
 
Microemulsions 
Microemulsions are thermodynamically stable, clear dispersions composed of a polar 
solvent, oil, surfactant, and co-surfactant. Microemulsions have demonstrated 
considerable potential for drug delivery due to their ability to solubilise highly hydrophobic 
drugs in both oral and intravenous administration (see Table 11). 
Tab. 11.   Marketed, lipid-based microemulsions. 
Marketed  
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Neoral
®  Cyclosporine A  Capsule (soft gelatin) 
Novartis 
Pharmaceuticals 
Corporation 
USA 
Fenogal
®  Fenofibrate  Capsule (hard gelatin)  SMB Laboratories  UK 
Sandimmune
®  Cyclosporine A  Capsule (soft gelatin) 
Novartis 
Pharmaceuticals 
Corporation 
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Oral solutions 
Oral solutions are usually applied by pediatric patients or patients with inability to swallow 
a tablet or capsule. Some lipid containing oral solutions are relatively simple formulations, 
containing a single excipient, while others are complex mixtures of surfactants, solvents, 
flavour, sweeteners, and salts (see Table 12). 
Tab. 12.   Marketed, lipid-based oral solutions. 
Marketed 
formulation 
Active molecule  Dosage form  Manufacturer  Country  
of sale 
Agenerase
®  Amprenavir  Oral solution  GlaxoSmithKline  USA 
Sustiva
®  Efavirenz  Oral solution  Bristol-Myers 
Squibb Company  USA 
Rocaltrol
®  Calcitriol  Oral solution  Roche 
Laboratories Inc.  USA 
 
Oral suspensions 
Similar to oral solutions, oral suspensions are usually intended for pediatric patients or for 
patients who cannot swallow a tablet or capsule. The suspensions are supplied in two 
bottles, the one contains drug encapsulated into solid microcapsules together with 
polymers and other excipients, while the other bottle contains the diluent composed of 
medium chain triglycerides, sucrose, lecithin, water, and strawberry flavor. Prior to 
administration, the contents of the two bottles are mixed to form the suspension (see 
Table 13).  
Tab. 13.   Marketed, lipid-based oral suspensions 
Marketed 
formulation 
API  Dosage form  Manufacturer  Country  
of sale 
Cipro 
TM  Ciprofloxacin  Oral suspension  Bayer Healthcare 
Pharmaceuticals Inc.  USA 
 
Conclusion 
Lipid-based formulations are an important tool for water-insoluble drugs as they offer the 
potential for enhancing drug absorption and oral bioavailability. The GI-tract  basically 
influences the performance of lipid-based formulations. Especially the chemistry and 
nature of the interaction of lipid digestion products with the aqueous contents of the GI-
tract changes according to digestion and solubilisation. Solid dosage forms of lipid 
formulations can improve stability, but may have lower drug loading and higher potential 
for drug crystallization. Thus, understanding and controlling phase transformations of the 
formulation are important. 
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